Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...
Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
At the JP Morgan Healthcare Conference, the firm highlighted two antibody-drug conjugates among 10 programs that will fuel ...
In December 2025, pimicotinib was approved by the China National Medical Products Administration (NMPA) for the treatment of adult patients with symptomatic TGCT for which surgical resection will ...
CHICAGO, IL, UNITED STATES, January 8, 2026 / EINPresswire.com / — The Institute of Medicine of Chicago (IOMC) is hosting its biennial convening, “State of Health of Chicago,” on Jan. 21, 2026, with ...
Merck’s global push for net-zero and renewable energy includes major operations in West Point, tying Montco to its ...
Inside a single-story brick building in Sorrento Mesa is a small lab sprinkled with beakers, test tubes and incubators that ...
Merck's MK-2214 drug received fast-track designation from the Food and Drug Administration for treatment of Alzheimer's disease. The Rahway, N.J., company said Monday that it would present data this ...
The daily pills are designed for use among those whose high cholesterol is not reaching healthy targets despite taking other medications. Thana Prasongsin via Getty Images An experimental pill ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback